Get the Daily Brief
Latest Biotech News
iOrganBio launches CellForge with $2M seed – AI to scale cell manufacturing
iOrganBio emerged from stealth with $2 million in seed funding and introduced CellForge, an AI‑driven cell manufacturing platform aimed at producing predictable, reproducible human cells and...
Kyverna CAR‑T shows deep, durable responses in small gMG cohort – moves toward phase III
Kyverna Therapeutics reported positive Phase II data for KYV‑101, a fully human, autologous CD19 CAR‑T with CD28 co‑stimulation, in generalized myasthenia gravis (gMG). In the Phase II portion of...
GSK pays $85M upfront for Empirico siRNA – a new oligonucleotide play in COPD
GSK inked an exclusive license with Empirico for a Phase I siRNA candidate, EMP‑012, focused on chronic obstructive pulmonary disease and other inflammatory respiratory diseases. The deal carries...
Intellia pauses CRISPR trials — on‑target liver toxicity flagged
Intellia Therapeutics halted enrollment and dosing in two clinical trials of its in vivo CRISPR candidate, nex‑z, after a patient was hospitalized with liver toxicity. The company notified...
Novartis buys Avidity for $12B — doubles down on RNA and neuroscience
Novartis agreed to acquire Avidity Biosciences for about $12 billion to gain three late‑stage antibody‑oligonucleotide conjugates (AOCs) focused on neuromuscular diseases. The deal adds delivery...
Lilly buys Adverum — one‑and‑done gene therapy enters big pharma orbit
Eli Lilly agreed to acquire Adverum in a deal focused on ixoberogene soroparvovec (ixo‑vec), a Phase III, single‑dose AAV gene therapy for wet age‑related macular degeneration (wAMD). Lilly said...
Merck’s Welireg clears two big trials — possible label expansion in kidney cancer
Merck reported positive results from two large trials of Welireg in renal cell carcinoma, outcomes that could expand use of the oral kinase inhibitor across kidney cancer populations. The data...
BridgeBio scores back‑to‑back Phase 3 wins — rare disease pipeline heats up
BridgeBio reported multiple late‑stage successes this week: encaleret met primary and key secondary endpoints in autosomal dominant hypocalcemia type 1 (ADH1), normalizing calcium and urine...
Kyverna’s CAR‑T shows promise in myasthenia gravis — small cohort, deep responses
Kyverna Therapeutics reported Phase 2 data for KYV‑101, a CD19 CAR‑T regimen, showing clinical responses in a small cohort of generalized myasthenia gravis (gMG) patients. Six treated patients...
Recursion delivers microglia phenomap — Roche pays milestone and options programs
Recursion provided Roche and Genentech with a whole‑genome microglia phenomap derived from a massive imaging perturbation set; Roche triggered a $30 million milestone payment that lifted total...
Regeneron doubles down on multispecifics — ModeX partnership tops $1B potential
Regeneron expanded its multispecific antibody capabilities via a strategic collaboration with ModeX Therapeutics. The agreement includes a modest upfront payment and potential development,...
GSK pays up for siRNA COPD candidate — Empirico deal underscores oligo push
GSK struck an agreement to license Empirico’s EMP‑012, a Phase 1 siRNA candidate for COPD, paying $85 million upfront with additional milestones that could push the deal value into the high...
Zag Bio emerges with $80M to rewire thymus tolerance — big‑name backers onboard
Zag Bio launched from stealth with roughly $80 million in capital to develop thymus‑targeted biologics designed to induce central immune tolerance via thymic regulatory T cell pathways. The...
Novartis pays $12B for Avidity — muscle-targeted RNA push
Novartis agreed to acquire Avidity Biosciences in a transaction valuing the RNA therapeutics developer at roughly $12 billion. The deal transfers three late-stage antibody-oligonucleotide...
Intellia pauses CRISPR Phase III... liver toxicity forces safety review
Intellia Therapeutics halted enrollment and dosing in two Phase III trials of its in vivo CRISPR candidate after a trial participant developed severe liver injury requiring hospitalization. The...
BridgeBio scores back‑to‑back Phase 3 wins — rare disease filings planned
BridgeBio Pharma reported multiple late‑stage successes this week, with its oral candidate encaleret meeting all primary and key secondary endpoints in autosomal dominant hypocalcemia type 1...
Eli Lilly, Nvidia... build pharma’s most powerful AI supercomputer
Eli Lilly and Nvidia announced a collaboration to build what they characterized as the most powerful supercomputer owned by a pharmaceutical company, aimed at training large AI models for drug...
Lilly acquires Adverum — bets on one‑time gene therapy for wAMD
Eli Lilly agreed to acquire Adverum Biotechnologies to secure ixoberogene soroparvovec (ixo‑vec), a one‑time AAV2 gene therapy in Phase III for wet age‑related macular degeneration (wAMD). Lilly...
Recursion delivers microglia phenomap to Roche — $30M milestone paid
Recursion Therapeutics reported delivery of a whole‑genome microglia ‘phenomap’ built from 46 million microglial cell images and perturbation data to Roche and Genentech under their collaboration,...
10x Genomics unveils next‑gen Chromium Flex — 384‑plex, automation‑ready
10x Genomics launched a next‑generation Chromium Flex assay designed to scale single‑cell experiments to high sample and cell numbers: up to 384 samples and the capacity to profile up to 100...